Bank of America group drops below 10% in Aptevo (APVO)
Bank of America Corporation, together with Bank of America N.A. and BofA Securities, Inc., filed a joint Form 4 to report that their combined beneficial ownership in Aptevo Therapeutics Inc. (APVO) has fallen below 10%.
Rhea-AI Filing Summary
Bank of America Corporation, together with Bank of America N.A. and BofA Securities, Inc., filed a joint Form 4 to report that their combined beneficial ownership in Aptevo Therapeutics Inc. (APVO) has fallen below 10%. The filing lists the reporting entities' Charlotte, NC addresses and includes authorized signatures dated 10/03/2025. The statement explains the purpose is to indicate these entities are no longer subject to Section 16 reporting obligations because their ownership decreased under the 10% threshold.
Positive
- Reporting obligation ended as combined ownership dropped below 10%, simplifying compliance
- Joint filing clarifies ownership change for investors and regulators
Negative
- Reduced transparency for APVO shareholders because Section 16 reporting by these entities will no longer be required
Insights
Bank of America group reduced holdings below 10%, ending Section 16 status.
The joint filing by Bank of America, BANA, and BofA Securities, Inc. formally notifies the market that their combined stake in Aptevo Therapeutics (APVO) is now under the 10% ownership threshold.
This change removes certain insider reporting requirements under Section 16, which can reduce short-term filing transparency about transactions by these entities but does not by itself disclose any specific share counts or recent buy/sell transactions in this Form 4.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Bank of America (BAC) report about its stake in Aptevo (APVO)?
When was the Form 4 filed and signed?
Which entities jointly filed this Form 4?
What is the immediate reporting implication of this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.